Lithium treatment

Phase 2Small molecule

VVA Office of Research and Development

Lithium treatment is one of 77 small molecule programs targeting Bipolar I Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bipolar I DisorderActive, not recruiting

Bipolar DisorderActive, not recruiting

Cognitive DisorderRecruiting

Bipolar I DisorderPreclinical

Active, not recruiting

Bipolar DisorderPreclinical

Active, not recruiting

Cognitive DisorderPhase 2

Recruiting

Competition

Competitive Landscape

89 competitors in Bipolar Disorder

#DrugCompanyPhaseTrials

Geodon

Pfizer

Approved

7 2

Lamictal

GGlaxo Dba Glaxosmithkline

Approved

19 3

Tegretol

Novartis

Approved

1 4

Vraylar

Keppra

Brintellix

Ritalin

Nolvadex

Vyvanse

Invega

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Recruiting

Cognitive Disorder

NCT06776848

Clinical

Trials by Indication[1]

Bipolar Disorder1 trial

Genetic Predictors of Lithium Response in Bipolar Disorder

Completed·VVA Office of Research and Development··NCT00252577·130 enrolled

Cognitive Disorder1 trial

A Pilot, Multicentre, Controlled, Open-label Study Evaluating 24 Months of Lithium Carbonate Treatment in Patients With TBR1-related Neurocognitive Disorder

Recruiting·—·Phase 1/2·NCT06776848·12 enrolled

Bipolar I Disorder1 trial

Optimizing Response to Li Treatment Through Personalized Evaluation of Individuals With Bipolar I Disorder: The R-LiNK Initiative

Unknown status·AAssistance Publique - Hôpitaux de Paris··NCT04209140·320 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Lithium treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lithium treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lithium treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — VA Office of Research and Development company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: VVA Office of Research and Development

Lithium treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Bipolar Disorder1 trial

Cognitive Disorder1 trial

Bipolar I Disorder1 trial

References

Drug Info

Quick Facts

Related News